When was Avery founded?

Avery was founded in 2013 and raised its 1st funding round 3 years after it was founded.

Where is Avery located?

Avery is headquartered in Tucson, United States.

Is Avery a funded company?

Avery is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 18, 2016.

When was the latest funding round of Avery?

Avery's latest funding was a $***** Grant (prize money) round on May 15, 2019, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $640M in funding in 2026 to date.

Where does Avery rank among its competitors?

Avery ranks 1208th amongst 1951 active competitors, of which 452 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Life Biosciences, which secured $80M in Apr, 2026.

Who are the top competitors of Avery?

Avery's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences. Among them, Life Biosciences secured the most recent funding round in April, 2026.

Avery - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developing immunomodulatory biologic therapeutics to improve human life. This company focuses on creating novel therapeutics within the biotechnology and pharmaceutical industries. Their core business model revolves around research and development, aiming to produce innovative biologic therapies. The company is dedicated to improving patient outcomes through immunomodulation. They are involved in the development of advanced medical solutions, potentially impacting various disease areas. The company operates as a research-driven entity, seeking to translate scientific discoveries into tangible therapeutic products. Their work contributes to the advancement of medical science and the availability of cutting-edge treatments.

Key Metrics

Founded Year

2013

Location

Tucson, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), May 15, 2019, $*****

Investors

HHS

Ranked

1208^th among 1951 active competitors

Similar Companies

Sutro Biopharma & 2661 more

View Avery's full profile

Avery has raised funding over 3 rounds. Its first funding round was on Aug 18, 2016. Its latest funding round was a Grant (prize money) round on May 15, 2019 for $*****. 1 investor participated in its latest round. Avery has 1 institutional investor.

Here is the list of recent funding rounds of Avery:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 15, 2019	5914204	Grant (prize money)	6009505	7886394	9574257	3153886
Jun 01, 2017	9200173	Conventional Debt	4925848	6945696	6608341	5350779
Aug 18, 2016	1072987	Grant (prize money)	6956546	5838879	3787548	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Avery's funding rounds and investors

The founders of Avery is Jordan Lancaster.

Here are the details of Avery's key team members:

Jordan Lancaster: Co-Founder of Avery.

View details of Avery's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avery include Sutro Biopharma, Synthego and Avidity Biosciences. Here is the list of Top 10 competitors of Avery, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 20 others	70/100
4th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
5th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Monashee Investment Management ... & 14 others	64/100
8th	Life Biosciences 2017, Boston (United States), Series D	Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases	$261M	Alpha Wave Global, Globalive Capital & 12 others	64/100
9th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 12 others	63/100
10th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
1208th	Avery 2013, Tucson (United States), Funding Raised	Developing immunomodulatory biologic therapeutics to improve human life	-	HHS	25/100